MedeliX
Start asking

Enoxaparin

Inhixa · ATC code B01AB05

Also known as: Enoksaparin, Enoxaparina, Énoxaparine · Brand names: Clexane, Crusia, Enoxaparin Becat, Enoxaparin Venipharm, Hepaxane, Ledraxen, Enoxaparin Becat Laboratorios Farmacéuticos Rovi, Ghemaxan, Lovenox, Axeparin, Enox, Oksapar, Venaperta

Key facts
Active substance
Enoxaparin
Drug class
Antithrombotic
ATC code
B01AB05
Authorisation
centrally authorised across the EU (EMA)
Dosage forms
Inhixa 2,000 IU (20 mg)/0.2 mL solution for injection in pre-filled syringe · Inhixa 4,000 IU (40 mg)/0.4 mL solution for injection in pre-filled syringe · Inhixa 6,000 IU (60 mg)/0.6 mL solution for injection in pre-filled syringe · Inhixa 8,000 IU (80 mg)/0.8 mL solution for injection in pre-filled syringe · Inhixa 10,000 IU (100 mg)/1 mL solution for injection in pre-filled syringe · Inhixa 12,000 IU (120 mg)/0.8 mL solution for injection in pre-filled syringe · Inhixa 15,000 IU (150 mg)/1 mL solution for injection in pre-filled syringe · Inhixa 30,000 IU (300 mg)/3 mL solution for injection in multidose container
Information as of
2026-11-03

Key facts

Enoxaparin (Inhixa, an EU biosimilar of enoxaparin sodium) is a low molecular weight heparin given by subcutaneous injection for prevention and treatment of venous thromboembolism, for acute coronary syndrome and to prevent clotting in the dialysis circuit.

What it is used for

  • Prophylaxis of venous thromboembolism in moderate and high risk surgical patients, including orthopaedic and cancer surgery
  • Prophylaxis in acutely ill medical patients with reduced mobility at increased risk of venous thromboembolism
  • Treatment of DVT and PE (excluding PE likely to require thrombolysis or surgery); extended treatment and prevention of recurrence in active cancer
  • Unstable angina and NSTEMI (with oral acetylsalicylic acid) and acute STEMI, including patients undergoing PCI
  • Prevention of thrombus formation in the extracorporeal circuit during haemodialysis

Dosing

  • Surgical prophylaxis: moderate risk 2,000 IU (20 mg) SC once daily for at least 7 to 10 days; high risk 4,000 IU (40 mg) once daily, started 12 hours before surgery; extended up to 5 weeks after major orthopaedic surgery
  • Medical patients: 4,000 IU (40 mg) SC once daily for at least 6 to 14 days
  • DVT/PE: 150 IU/kg (1.5 mg/kg) once daily in uncomplicated patients, otherwise 100 IU/kg (1 mg/kg) twice daily; average period 10 days
  • Unstable angina/NSTEMI: 100 IU/kg (1 mg/kg) SC every 12 hours with antiplatelet therapy, usually 2 to 8 days
  • Acute STEMI: 3,000 IU (30 mg) IV bolus plus 100 IU/kg (1 mg/kg) SC, then every 12 hours; aged 75 or older no bolus and 75 IU/kg (0.75 mg/kg) every 12 hours
  • Creatinine clearance 15-30 mL/min: dose reduction to once-daily regimens; not recommended below 15 mL/min; not for intramuscular use

Contraindications

  • Hypersensitivity to enoxaparin, heparin or its derivatives including other LMWHs, or any excipient
  • Immune-mediated heparin-induced thrombocytopenia (HIT) within the past 100 days or circulating antibodies
  • Active clinically significant bleeding or high bleeding risk (recent haemorrhagic stroke, gastrointestinal ulcer, recent brain, spinal or eye surgery, oesophageal varices, vascular malformations)
  • Spinal, epidural or loco-regional anaesthesia within 24 hours of treatment-dose enoxaparin

Important warnings

  • Not interchangeable unit for unit with other LMWHs; record name and batch number of the product
  • HIT: measure platelet counts before and regularly during treatment; stop if platelets fall by 30 to 50 % of the initial value
  • Bleeding at any site; caution with impaired haemostasis, peptic ulcer, recent ischaemic stroke, severe hypertension or drugs affecting haemostasis
  • Neuraxial haematoma with spinal/epidural anaesthesia or puncture, possibly causing permanent paralysis
  • Renal impairment, elderly (especially eighty years and older), low body weight: higher exposure and bleeding risk; mechanical heart valves not adequately studied
  • Hyperkalaemia through aldosterone suppression; skin necrosis, cutaneous vasculitis and AGEP require stopping

Side effects

  • Haemorrhage, haemorrhagic anaemia, thrombocytopenia and thrombocytosis
  • Very common hepatic enzyme increases
  • Injection site haematoma, pain and other site reactions; urticaria, pruritus, erythema
  • Allergic reactions, headache
  • Rare: spinal haematoma, anaphylaxis, immuno-allergic thrombocytopenia with thrombosis, hyperkalaemia, osteoporosis after long-term therapy

Interactions

  • Not recommended unless strictly indicated: systemic salicylates, anti-inflammatory doses of acetylsalicylic acid, NSAIDs including ketorolac, thrombolytics and other anticoagulants
  • With caution: platelet aggregation inhibitors (acetylsalicylic acid, clopidogrel, ticlopidine, glycoprotein IIb/IIIa antagonists) and systemic glucocorticoids
  • Drugs increasing potassium: careful clinical and laboratory monitoring

Pregnancy and breastfeeding

  • No evidence of placental passage in the second and third trimester; use only if the physician has established a clear need; withdraw before planned epidural anaesthesia
  • Pregnant women with mechanical heart valves: valve thrombosis with maternal and foetal death reported
  • Can be used during breastfeeding

Summary of the official product information, written with AI on 2026-11-03. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.

Full official text →

Common questions – ask Medelix

For patients

Package leaflet, verbatim

This product has no separate US patient information.

Authorisation and brand names by country

Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.

EU – centrally authorised (all member states)

  • Inhixa · biosimilarTechdow Pharma Netherlands B.V. · EMEA/H/C/004264

Source: European Medicines Agency (EMA), product information

Germany

  • ClexaneSanofi-Aventis Deutschland Gmbh · 8 register entries
  • CrusiaLaboratorios Farmacéuticos Rovi, S.A · 1 register entry
  • Enoxaparin BecatLaboratorios Farmacéuticos Rovi, S.A · 5 register entries
  • Enoxaparin VenipharmVenipharm · 1 register entry
  • HepaxaneChemi S.P.A. · 1 register entry
  • LedraxenVenipharm · 1 register entry

Source: EMA – Article 57 product data (EU/EEA), as of 2026-11-03

Austria

  • Enoxaparin Becat Laboratorios Farmacéuticos RoviLaboratorios Farmacéuticos Rovi, S.A · 2 register entries
  • GhemaxanChemi S.P.A. · 1 register entry
  • LedraxenVenipharm · 1 register entry
  • LovenoxSanofi-Aventis Gmbh Osterreich · 1 register entry

Source: EMA – Article 57 product data (EU/EEA), as of 2026-11-03

Turkey

  • AxeparinVEM İLAÇ SAN. VE TİC. A.Ş. · 9 register entries
  • ClexaneSANOFİ SAĞLIK ÜRÜNLERİ LTD. ŞTİ. · 7 register entries
  • CrusiaDEM İLAÇ SAN. VE TİC. A.Ş. · 2 register entries
  • EnoxATABAY KİMYA SAN. VE TİC. A.Ş. · 6 register entries
  • OksaparKOÇAK FARMA İLAÇ VE KİMYA SAN. A.Ş. · 6 register entries
  • VenapertaPOLİFARMA İLAÇ SAN. VE TİC. A.Ş. · 4 register entries

Source: TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, as of 2026-11-03

Brand names in 27 more European countries
Belgium
Clexane, Enoxaparine Becat Laboratorios Farmacéuticos Rovi, Ghemaxan
Bulgaria
Клексан
Croatia
Clexane, Ledraxen, Losmina
Cyprus
Clexane, Ledraxen
Czechia
Clexane, Ledraxen, Losmina
Denmark
Enoxaparin Becat Laboratorios Farmacéuticos Rovi, Ghemaxan
Estonia
Clexane, Ledraxen, Losmina
Finland
Enoxaparin Becat Laboratorios Farmacéuticos Rovi, Ghemaxan, Ledraxen
France
Crusia, Enoxaparine Arrow, Enoxaparine Becat, Enoxaparine Biogaran, Enoxaparine Crusia, Enoxaparine Eg, Enoxaparine Teva, Enoxaparine Venipharm, Enoxaparine Zentiva, Ghemaxan, Ledraxen, Lovenox
Greece
Clexane, Enoxaparin Rovi, Havetra
Hungary
Clexane, Hepaxane, Ledraxen, Losmina
Iceland
Inhixa, Klexane, Ledraxen
Ireland
Clexane, Ghemaxan, Ledraxen
Italy
Clexane, Enoxaparina Laboratorios Farmacéuticos Rovi, Enoxaparina Rovi, Ghemaxan, Ledraxen, Rovinadil
Latvia
Clexane, Ledraxen, Losmina
Lithuania
Ledraxen
Luxembourg
Clexane, Enoxaparin Venipharm, Enoxaparine Becat Laboratorios Farmacéuticos Rovi, Ledraxen
Malta
Clexane, Ledraxen
Netherlands
Enoxaparine Becat Laboratorios Farmacéuticos Rovi, Ghemaxan
Norway
Enoxaparin Becat Laboratorios Farmacéuticos Rovi, Ghemaxan, Inhixa, Klexane, Ledraxen
Poland
Clexane, Ledraxen, Neoparin
Portugal
Enoxaparina Rovi, Hepaxane, Ledraxen, Lovenox
Romania
Clexane, Hepaxane, Losmina
Slovakia
Clexane, Ghemaxan, Ledraxen
Slovenia
Clexane, Enoksaparin Rovi, Ledraxen
Spain
Clexane, Crusia, Enoxaparina Rovi, Hepaxane, Ledraxen
Sweden
Enoxaparin Becat Laboratorios Farmacéuticos Rovi, Ghemaxan, Klexane, Ledraxen

EMA – Article 57 product data (EU/EEA), 2026-11-03

Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.

Other substances in the same group

Another question about this substance?

Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.

Sources

  1. European Medicines Agency. Inhixa – EPAR, Product Information. 2026-11-03. https://www.ema.europa.eu/en/documents/product-information/inhixa-epar-product-information_en.pdf
  2. EMA – Article 57 product data (EU/EEA), 2026-11-03. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database
  3. EMA – Article 57 product data (EU/EEA), 2026-11-03. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database
  4. TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, 2026-11-03. https://www.titck.gov.tr/dinamikmodul/85
  5. Wikidata (CC0): ATC B01AB.

Editorial: Medelix editorial team · last updated 2026-11-03 · How these pages are made · Report an error

Source: European Medicines Agency (EMA), product information. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.